Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population.
Despite the favorable prognosis for medullary breast cancer (MBC), the guidelines for the use of adjuvant chemotherapy for MBC have not been clearly established. This study investigated the prognostic role of adjuvant chemotherapy in Korean patients with node-negative (N0), triple-negative (TN) MBC...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4642937?pdf=render |
| _version_ | 1818034509008863232 |
|---|---|
| author | SeungTaek Lim Se Ho Park Heong Kyu Park Min Hee Hur Se Jeong Oh Young Jin Suh |
| author_facet | SeungTaek Lim Se Ho Park Heong Kyu Park Min Hee Hur Se Jeong Oh Young Jin Suh |
| author_sort | SeungTaek Lim |
| collection | DOAJ |
| description | Despite the favorable prognosis for medullary breast cancer (MBC), the guidelines for the use of adjuvant chemotherapy for MBC have not been clearly established. This study investigated the prognostic role of adjuvant chemotherapy in Korean patients with node-negative (N0), triple-negative (TN) MBC patients.We included data from 252 patients with N0 TN MBC, obtained from the Korean Breast Cancer Registry database. Patients were categorized as those who did not undergo adjuvant chemotherapy (group I) or those who did (group II). Clinicopathological characteristics, breast cancer-specific survival (BCSS), and overall survival (OS) were compared between the groups. In addition, a subgroup analysis for survival based on tumor size was conducted.A total of 252 N0 TN MBC patients with tumor sizes >1 cm who were diagnosed between April 1997 and March 2011 were enrolled. The median age was 44.95 years (range, 25-72 years), and the median follow-up period was 93.94 months (range, 23-195 months). Overall, the BCSS and OS in group II (97.3% and 97.3%, respectively) were significantly better compared with those in group I (89.2% and 86.2%, respectively). In the subgroup analysis, in patients with tumors >2 cm in size, those in group II had significant better BCSS and OS (97.5% and 97.5%, respectively) compared with those in group I (78.3% and 73.9%, respectively). In contrast in those with tumors 1-2 cm in size, there were no significant differences in BCSS and OS between the groups (both 97.1% for group I, and 95.2% and 92.9%, respectively for group II). Multivariate analysis revealed that adjuvant chemotherapy significantly improved BCSS (P = 0.009) and OS (P = 0.007), but only for patients with larger tumors (>2 cm).In patients with N0 TN MBC, adjuvant chemotherapy had a significant clinical survival benefit, but only in those with tumors >2 cm. |
| first_indexed | 2024-12-10T06:40:17Z |
| format | Article |
| id | doaj.art-87fd9036c4fa4553b4963ed895c6b5ee |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-10T06:40:17Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-87fd9036c4fa4553b4963ed895c6b5ee2022-12-22T01:58:48ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-011011e014020810.1371/journal.pone.0140208Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population.SeungTaek LimSe Ho ParkHeong Kyu ParkMin Hee HurSe Jeong OhYoung Jin SuhDespite the favorable prognosis for medullary breast cancer (MBC), the guidelines for the use of adjuvant chemotherapy for MBC have not been clearly established. This study investigated the prognostic role of adjuvant chemotherapy in Korean patients with node-negative (N0), triple-negative (TN) MBC patients.We included data from 252 patients with N0 TN MBC, obtained from the Korean Breast Cancer Registry database. Patients were categorized as those who did not undergo adjuvant chemotherapy (group I) or those who did (group II). Clinicopathological characteristics, breast cancer-specific survival (BCSS), and overall survival (OS) were compared between the groups. In addition, a subgroup analysis for survival based on tumor size was conducted.A total of 252 N0 TN MBC patients with tumor sizes >1 cm who were diagnosed between April 1997 and March 2011 were enrolled. The median age was 44.95 years (range, 25-72 years), and the median follow-up period was 93.94 months (range, 23-195 months). Overall, the BCSS and OS in group II (97.3% and 97.3%, respectively) were significantly better compared with those in group I (89.2% and 86.2%, respectively). In the subgroup analysis, in patients with tumors >2 cm in size, those in group II had significant better BCSS and OS (97.5% and 97.5%, respectively) compared with those in group I (78.3% and 73.9%, respectively). In contrast in those with tumors 1-2 cm in size, there were no significant differences in BCSS and OS between the groups (both 97.1% for group I, and 95.2% and 92.9%, respectively for group II). Multivariate analysis revealed that adjuvant chemotherapy significantly improved BCSS (P = 0.009) and OS (P = 0.007), but only for patients with larger tumors (>2 cm).In patients with N0 TN MBC, adjuvant chemotherapy had a significant clinical survival benefit, but only in those with tumors >2 cm.http://europepmc.org/articles/PMC4642937?pdf=render |
| spellingShingle | SeungTaek Lim Se Ho Park Heong Kyu Park Min Hee Hur Se Jeong Oh Young Jin Suh Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population. PLoS ONE |
| title | Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population. |
| title_full | Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population. |
| title_fullStr | Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population. |
| title_full_unstemmed | Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population. |
| title_short | Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population. |
| title_sort | prognostic role of adjuvant chemotherapy in node negative n0 triple negative tn medullary breast cancer mbc in the korean population |
| url | http://europepmc.org/articles/PMC4642937?pdf=render |
| work_keys_str_mv | AT seungtaeklim prognosticroleofadjuvantchemotherapyinnodenegativen0triplenegativetnmedullarybreastcancermbcinthekoreanpopulation AT sehopark prognosticroleofadjuvantchemotherapyinnodenegativen0triplenegativetnmedullarybreastcancermbcinthekoreanpopulation AT heongkyupark prognosticroleofadjuvantchemotherapyinnodenegativen0triplenegativetnmedullarybreastcancermbcinthekoreanpopulation AT minheehur prognosticroleofadjuvantchemotherapyinnodenegativen0triplenegativetnmedullarybreastcancermbcinthekoreanpopulation AT sejeongoh prognosticroleofadjuvantchemotherapyinnodenegativen0triplenegativetnmedullarybreastcancermbcinthekoreanpopulation AT youngjinsuh prognosticroleofadjuvantchemotherapyinnodenegativen0triplenegativetnmedullarybreastcancermbcinthekoreanpopulation |